Kelleher Financial Advisors Buys 4,797 Shares of Pfizer Inc. $PFE

Kelleher Financial Advisors increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 12.0% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 44,793 shares of the biopharmaceutical company’s stock after acquiring an additional 4,797 shares during the quarter. Kelleher Financial Advisors’ holdings in Pfizer were worth $1,086,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of PFE. denkapparat Operations GmbH raised its holdings in shares of Pfizer by 12.6% in the second quarter. denkapparat Operations GmbH now owns 33,572 shares of the biopharmaceutical company’s stock valued at $814,000 after purchasing an additional 3,750 shares during the last quarter. Wealth Alliance LLC grew its position in Pfizer by 19.1% in the 2nd quarter. Wealth Alliance LLC now owns 65,027 shares of the biopharmaceutical company’s stock worth $1,576,000 after purchasing an additional 10,437 shares in the last quarter. Jupiter Asset Management Ltd. lifted its position in shares of Pfizer by 10.0% during the 2nd quarter. Jupiter Asset Management Ltd. now owns 1,725,979 shares of the biopharmaceutical company’s stock worth $41,838,000 after buying an additional 156,952 shares in the last quarter. SBI Securities Co. Ltd. boosted its stake in shares of Pfizer by 15.0% in the 2nd quarter. SBI Securities Co. Ltd. now owns 419,629 shares of the biopharmaceutical company’s stock worth $10,172,000 after buying an additional 54,578 shares during the last quarter. Finally, Westbourne Investment Advisors Inc. increased its position in shares of Pfizer by 20.2% during the second quarter. Westbourne Investment Advisors Inc. now owns 23,810 shares of the biopharmaceutical company’s stock valued at $577,000 after acquiring an additional 4,000 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Up 4.5%

Shares of PFE stock opened at $25.49 on Wednesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The business’s fifty day moving average is $24.75 and its 200 day moving average is $24.41. The company has a market capitalization of $144.93 billion, a PE ratio of 13.56, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.69.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.79 by $0.08. The firm had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. Pfizer’s dividend payout ratio is 100.00%.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Morgan Stanley reduced their price objective on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday, October 10th. UBS Group reissued a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a research report on Wednesday, October 1st. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Bank of America boosted their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $30.00 price target on shares of Pfizer in a report on Friday, October 31st. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Pfizer has an average rating of “Hold” and a consensus target price of $28.18.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.